A Clinical Study Of Enadenotucirev Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer

Trial Profile

A Clinical Study Of Enadenotucirev Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Enadenotucirev (Primary)
  • Indications Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms EVOLVE
  • Sponsors PsiOxus Therapeutics
  • Most Recent Events

    • 11 Oct 2016 Results assessing the pattern of enadenotucirev delivery within tumors in patients with colon, lung, bladder and renal carcinoma (n=17) presented at the 41st European Society for Medical Oncology Congress.
    • 16 Jul 2016 This trial has been completed in Belgium (End date:2016-04-29) as per European Clinical Trials Database record.
    • 20 May 2016 The trial was prematurely ended in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top